CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease

• Published in: Cardiovascular diabetology Vol. 21; no. 1; pp. 1 - 185
• Main Authors: Chang, Ting-Ting, Chen, Ching, Chen, Jaw-Wen
• Format: Journal Article
• Language: English
• Published: London BioMed Central 15.09.2022; BMC
• Subjects: Abdomen; Angiogenesis; Aortic aneurysms; Atherosclerosis; Bone marrow; Cardiovascular disease; Cardiovascular diseases; Chemokine; Chemokine CC motif ligand 7; Chemokines; Chronic kidney disease; Coronary vessels; Diabetes; Diabetes mellitus; Diabetic kidney disease; Gene expression; Heart attacks; Hypertension; Inflammation; Kidney diseases; Kinases; Ligands; Macrophages; Monocytes; Neutrophils; Pathogenesis; Physiology; Proteins; Review; Smooth muscle; Tumor necrosis factor-TNF; Veins & arteries
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-022-01626-1

Abstract Chemokines are key components in the pathology of chronic diseases. Chemokine CC motif ligand 7 (CCL7) is believed to be associated with cardiovascular disease, diabetes mellitus, and kidney disease. CCL7 may play a role in inflammatory events by attracting macrophages and monocytes to further amplify inflammatory processes and contribute to disease progression. However, CCL7-specific pathological signaling pathways need to be further confirmed in these chronic diseases. Given the multiple redundancy system among chemokines and their receptors, further experimental and clinical studies are needed to clarify whether direct CCL7 inhibition mechanisms could be a promising therapeutic approach to attenuating the development of cardiovascular disease, diabetes mellitus, and kidney disease.